Important upcoming anticipated milestones for MoonLake (GlobeNewswire) - Nov 5, 2025 - "Q1 2026: Primary endpoint readout of the Phase 2 S-OLARIS trial in axSpA; Q2 2026: 52 weeks data of the VELA-1 and VELA-2 trials in HS; Q2 2026: Primary endpoint readout of the Phase 3 IZAR-1 trial in PsA; Q2 2026: Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HS; Q3 2026: Initiate Phase 3 trial in PPP; Q3/Q4 2026: Submission of a BLA; H2 2026: Primary endpoint readout of the Phase 3 IZAR-2 trial in PsA."
Clinical data • FDA filing • New P3 trial • Ankylosing Spondylitis • Hidradenitis Suppurativa • Psoriasis • Psoriatic Arthritis
|